The USFDA conducted a general GMP (Good Manufacturing Practices) Inspection of Piramal Pharma Limited's facility at Aurora, Canada from 26th May 2025 to 30th May, 2025.
The inspection was completed successfully with Zero Form - 483 observations and No Action Indicated (NAI) designation.
The company remains committed to maintain the highest standards of compliance.
Subscribe To Our Newsletter & Stay Updated
